Azithromycin: a new 15-membered macrolide
1Pfizer Pharmaceuticals Group, Pfizer, Inc., New York, New York, USA.
Abstract:
Azithromycin is the sole member of the macrolide sub-class, the azalides. Due to its altered chemical structure, azithromycin is characterized by a broader spectrum of activity, lower incidence of adverse events and drug interactions and a pharmacokinetic profile, that is in contrast to existing macrolides. Because of its high and prolonged cellular and tissue concentrations, patients are able to complete a course of azithromycin within a shorter timeframe as compared to other antibiotics. Azithromycin is widely used in the treatment of adult and pediatric respiratory tract infections. Continued research into azithromycin's utility has resulted in indication development for several devastating infections such as trachoma. Large-scale studies of its activity against Chlamydia pneumoniae related atherosclerosis are underway.
Insights
Azithromycin, an azalide antibiotic, offers a broader spectrum of activity and improved pharmacokinetics compared to other macrolides. Its high tissue concentrations enable shorter treatment durations for various infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Azithromycin is a unique azalide antibiotic, distinct from traditional macrolides.
- Its altered chemical structure confers advantages over existing macrolides.
Purpose of the Study:
- To review the pharmacological and clinical profile of azithromycin.
- To highlight its efficacy in treating various infections.
Main Methods:
- Literature review of azithromycin's properties and clinical applications.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Examination of clinical trial outcomes.
Main Results:
- Azithromycin exhibits a broader spectrum of activity and a favorable safety profile.
- It achieves high, prolonged cellular and tissue concentrations.
- Shorter treatment courses are possible compared to other antibiotics.
Conclusions:
- Azithromycin is effective for respiratory tract infections in adults and children.
- New indications, including trachoma, are being developed.
- Ongoing research explores its role in treating Chlamydia pneumoniae-related atherosclerosis.
More Related Videos
09:09High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Related Concept Videos
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Streptococcal Pharyngitis
Atypical Pneumonia
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance
